|
|
 |
|
Viewing report
|
|
|
|
Czech Republic Pharmaceuticals and Healthcare Report Q3 2009
Business Monitor International, July 2009, Pages: 78
The Czech Republic Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the Czech Republic's pharmaceuticals and healthcare industry.
The Czech pharmaceutical market is among the most developed in Central and Eastern Europe (CEE). Harmonised regulations, high per-capita spending and strong growth have attracted pharmaceutical companies of both research and generic orientation to establish a significant presence in the country.
Through to 2013 the author forecasts a solid, if unspectacular compound annual growth rate (CAGR) for pharmaceutical expenditure of 5.4%.
The Czech Republic is ranked second in the Business Environment Rankings for Q309. Above average scores in all sub-categories reinforces the country’s status as a developed and attractive market.
However, the author believes that the Czech Republic’s regulatory environment is becoming increasingly unattractive to innovative pharmaceutical companies. New rules implemented by the Ministry of Health will require doctors to prescribe drugs by active substance, rather than brand, with pharmacists then dispensing the cheapest version of a medicine.
The Czech Republic was present on the Pharmaceutical Research and Manufacturers of America (PhRMA)’s Special 301 Submission 2009 owing to a negative pricing and reimbursement regime, which constitutes a ‘significant barrier to imported innovative pharmaceuticals’ – likely a result of the negative impact of the country’s jumbo reference pricing groups. The report also criticises restrictive prescription limitations and closely monitored physician drug budgets.
The implementation of healthcare fees for patients saved the Czech health system over CZK10bn (US$498mn) during 2008, according to data from the Ministry of Health. Approximately half of this figure was achieved through fee collection, and the rest through associated cost savings. Meanwhile the single biggest combined savings indicator was pharmacy prescription behaviour, which through the collection of a CZK30 (US$1.48) fee per prescription and a reduction in unnecessary dispensing of medicines is estimated to have cut expenditure by CZK6.07bn (US$0.30bn).
The debacle over the validity and enforcement of prescription fees is a major challenge for pharmacies. In H109 the termination of healthcare fees in certain regions resulted in income figures declining by 30-70% for pharmacies in regions where fees still applied. As a result, private pharmacies had to reduce their operating hours and were forced into staff cutbacks in order to offset the deteriorating financial figures.
Customers who bought this item also bought
Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
Czech Republic Pharmaceuticals and Healthcare Report Q3 2007
The Pharmaceutical Market: Czech Republic
Czech Republic Pharmaceuticals and Healthcare Report Q4 2009
Czech Republic Pharmaceuticals and Healthcare Report Q2 2008
Czech Republic Pharmaceuticals and Healthcare Report Q4 2008
Executive Report on Strategies in Czech Republic
Czech Republic Pharmaceuticals and Healthcare Report Q2 2009
Czech Republic Pharmaceuticals and Healthcare Report Q3 2008
Pharmaceutical Industry in Czech Republic
OTC Healthcare in the Czech Republic to 2010
The Expenditure Report - Czech Republic
|
|
|
|
